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Abstract
Epstein-Barr virus (EBV) has been implicated in the pathogenesis of rheumatoid arthritis (RA) on the basis of indirect
evidence, such as its presence in affected joint tissues, antigenic cross reactions between EBV and human proteins, and
elevated humoral and cellular anti-EBV immune responses in patients. Here we report development of erosive arthritis
closely resembling RA in humanized mice inoculated with EBV. Human immune system components were reconstituted in
mice of the NOD/Shi-scid/IL-2Rc
null (NOG) strain by transplantation with CD34
+ hematopoietic stem cells isolated from cord
blood. These humanized mice were then inoculated with EBV and examined pathologically for the signs of arthritis. Erosive
arthritis accompanied by synovial membrane proliferation, pannus formation, and bone marrow edema developed in fifteen
of twenty-three NOG mice transplanted with human HSC and inoculated with EBV, but not in the nine NOG mice that were
transplanted with HSC but not inoculated with EBV. This is the first report of an animal model of EBV-induced arthritis and
strongly suggest a causative role of the virus in RA.
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Introduction
A number of observations including those by the authors have
suggested the involvement of Epstein-Barr virus (EBV) in the
pathogenesis of rheumatoid arthritis (RA)[1,2,3,4,5,6,7]. For
example, circulating EBV load is higher in RA patients than in
healthy controls [8] and activated CD8-positive cells specific to
EBV are commonly seen in RA patients[9]. Further, studies have
reported that a large number of T cells specific to EBV-encoded
proteins are present in the affected joints of RA patients[10], that
interference of suppressor T cells specific to EBV plays a role
in RA[11], and that RA patients have abnormally large
numbers of EBV-infected B cells in the blood[12]. We have
reported on the decreased expression of the gene coding for
the signaling lymphocytic activation molecule-associated protein
(SAP) (also known as the Src homology 2 domain-containing
protein 1A (SH2D1A)) that is supposed to have critical roles in the
elimination of EBV-infected B cells by cytotoxic T cells and NK
cells [13]. This reduced expression of SAP might lead to the failure
of the immune system to eliminate EBV-infected B cells in RA
patients [14]. These studies, however, provided only indirect
evidence for the involvement of EBV in RA and there have been
no published reports on EBV-induced arthritis in experimental
animals.
Although model animals for EBV infection are required to
examine a causal relationship between EBV and RA, there has
been no appropriate animal models suitable for this purpose. EBV
can infect only limited primate species and does not infect normal
mice. Recently, we developed a humanized mouse model of
EBV infection, based on the NOD/Shi-scid/IL-2Rc
null (NOG)
mouse strain[15], that can reproduce key aspects of human EBV
infection, such as lymphoproliferative disorder, asymptomatic
persistent infection, and humoral and T cell–mediated immune
responses[15]. In this model, where human immune components
were reconstituted by transplantation with cord blood-derived
CD34
+ stem cells, inoculation with high-dose EBV (,1610
3 50%
transformation dose [TD50]) resulted in the development of
lymphoproliferative disorder, whereas inoculation with low-dose
virus (,1610
1 TD50) tended to cause apparently asymptomatic
persistent infection [15]. Immunological analyses of these mice
demonstrated the presence of EBV-specific CD8
+ T cells that
inhibit transformation of autologous B lymphocytes by the virus
[16]. In the present study, we characterized histopathology of joint
tissues obtained from EBV-infected humanized NOG mice and
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those of RA.
Materials and Methods
Ethics Statement and Preparation of humanized mice
NOG mice were obtained from the Central Institute for
Experimental Animals (Kawasaki, Japan), and protocols for
experiments with NOG mice were approved by the Institutional
Animal Care and Use Committee of the National Institute of
Infectious Diseases (NIID; Tokyo, Japan) (certification number
206061, 14th. April 2006). Cord blood was obtained from the
Tokyo Cord Blood Bank (Tokyo, Japan) after acquiring informed
consent from the parents of the donors. Protocols for experiments
with human materials were approved by the Institutional Review
Boards of the National Research Institute for Child Health
and Development (Tokyo, Japan) (certification number 139, 22th.
March 2005), the NIID (certification number 1, 17th. October
1997), and the Tokyo Cord Blood Bank (certification number 06-
17-02, 18th. August 2006). Isolation of human CD34
+ HSCs from
cord blood using the MACS Direct CD34 Progenitor Cell
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany),
their intravenous injection (1610
4 to 1.2610
5 cells/mouse) into
6- to 10-week-old female NOG mice, and characterization
of reconstitution of human hematoimmune system components
in these mice were performed as described elsewhere[17]. NOG
mice were not irradiated prior to transplantation with CD34
+
HSCs, because they lived significantly longer after humanization
and satisfactory development of human immune system compo-
nents were observed without irradiation [18]. NOG mice
in which human hematoimmune system components were
reconstituted are referred to here as humanized NOG (hNOG)
mice.
Analysis on the reconstitution of human lymphoid
system components in hNOG mice
Peripheral blood mononuclear cells were isolated weekly from
NOG mice following transplantion with human CD34
+ stem cells
and examined for the reactivity with the following antibodies by
flow cytometry: FITC-conjugated anti–human CD45 (J.33), CD3
(UCHT1), CD4 (13B8.2), CD19 (J4.119), and CD45RO (UCHL1)
(all from Beckman Coulter, Brea, CA); PE-conjugated anti–human
CD4 (13B8.2), CD8 (B9.11), CD19 (J4.119), CD45RA (ALB11)
(all from Beckman Coulter), and CXCR4 (44717; R&D Systems,
Minneapolis, MN); anti–mouse CD45 (YW62.3; Beckman Coul-
ter); ECD-conjugated anti–human CD45 (J.33; Beckman Coulter);
and PC5-conjugated anti–human CD8 (T8) and CD14 (Rm052)
(all from Beckman Coulter). Flow cytometric analysis was conducted
by2-or4-colorstainingusingtheEpicsXLflowcytometer(Beckman
Coulter).
Experimental EBV infection and quantification of viral
DNA
Supernatant fluid of Akata cell culture was prepared as
described previously[15] and used as EBV inoculum. EBV dose
in 50% transformation dose (TD50) was determined by a standard
method as described previously[15]. EBV was inoculated
intravenously through the tail vein. Peripheral blood EBV DNA
load was quantified by real-time polymerase chain reaction (PCR)
based on the TaqMan system (Applied Biosystems), as described
elsewhere[19]. As a control, nine hNOG mice were left un-
infected; among them four mice were inoculated with supernatant
fluid of EBV-negative Akata cell culture.
Histopathology, in situ hybridization (ISH), and
immunohistochemistry
hNOG mice were sacrificed 1 to 12 months after inoculation
with EBV and their major joints including knees and ankles were
removed and fixed in 10% formalin solution. These specimens
were embedded in paraffin and stained with hematoxylin-eosin
(HE) for histological examinations. For phenotypic analysis of
proliferating lymphocytes, immunostaining with the antibodies
specific to human CD3 (DAKO, A0452), CD4 (Leica, NCL-CD4-
1F6), CD8 (Leica, NCL-CD8-4B11), CD20 (DAKO, M0755) and
CD68 (DAKO, M0876) was performed on paraffin sections. EBV
was detected by in-situ hybridization (ISH) with EBV-encoded
small RNA (EBER) probes (DAKO, Y5200).
Statistical Analysis
Fisher’s exact test was used for categorical data. Analyses were
performed using JMP 7.0.2 for Windows (SAS Institute Inc., Cary,
NC). All tests were two-tailed, with differences reported as
significant when p values were less than 0.01.
Results
Twenty-three hNOG mice, prepared with CD34
+ cells isolated
from ten different cord blood samples and inoculated with EBV
were examined histopathologically for the presence of erosive
arthritis. The number of transplanted CD34
+ cells (0.1–1.2610
5
cells), days from transplantation with CD34
+ cells to inoculation
with EBV (106–197 days), dose of EBV inoculated (10
0–10
3 TD50),
daysfromEBVinoculationtoautopsy(26–320days)foreachmouse
are described in Table S1. As a control, nine hNOG mice prepared
with CD34
+ cells isolated from three different cord blood samples
and not inoculated with EBV were examined similarly (Table S1).
Among them, four mice were mock inoculated with culture
supernatant of EBV-negative Akata cells. HE staining of major
joints including knees and ankles revealed synovial proliferation and
infiltration of inflammatory cells in the synovium in 15 of the 23
EBV-infected hNOG mice (65%), whereas none of the nine control
hNOG mice showed these signs of arthritis (P=0.001 by the two-
tailed Fisher’s exact test) (Fig. 1A and Table 1). Development of
arthritis was not dependent on viral dose, because hNOG mice
developed arthritis following EBV inoculation at each dose (10
0,
10
1,1 0
2,1 0
3 TD50) (Table S1). The earliest time point when
arthritis was observed was 26 days post-infection and it was seen as
late as 320 days post-infection. In a fraction of examined mice,
granulation tissue overgrew the bearing surface of the joint and was
associated with the breakdown of the articular surface. Further-
more, multinuclear giant cells similar to osteoclasts were seen in the
granulation tissue that invaded the bone on the joint edge
(Figure 1A). This histology is remarkably similar to the pannus
formation seen in erosive arthritis characteristic to RA. In the bone
marrow adjacent to inflamed joints, infiltration of activated
mononuclear cells generated a histology reminiscent of bone
marrow edema characteristic to RA (Fig. 1A).
Immunostaining with monoclonal antibodies revealed a large
number of CD3-positive T cells among the proliferating cells in the
synovial tissue (Fig. 1B). Both CD4
+ and CD8
+ cells were identified.
There were also a few CD20
+B cells and CD68
+macrophages. When
the bone marrow adjacent to inflamed joint tissue was examined by
immunostaining, CD3-positive cells and CD4-positive cells were
detected, while almost no cells exhibited positive CD20 staining
(Figure 1B). It should be noted that because NOG mice lack T, B, and
NK lymphocytes completely and human-specific antibodies were used
here, all lymphocytes detected in hNOG mouse tissues are considered
to be of human origin. EBER ISH revealed only few EBV-infected
Mouse Model for EBV-Induced Arthritis
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numerous EBV-infected cells were detected in the bone marrow near
the affected joints (Fig. 1A).
Discussion
Erosive arthritis was observed in 15 among the 23 hNOG mice
infected with EBV but not in nine control mice that were
reconstituted with human immune system components but not
inoculated with EBV. The incidence of erosive arthritis is
significantly elevated among EBV-infected mice compared with
control uninfected mice (P=0.001 by the two-tailed Fisher’s exact
test). This erosive arthritis is accompanied by pannus formation,
synovial membrane proliferation, inflammatory cell infiltration to
the synovium, and bone marrow edema, rendering it closely
similar to the tissue of RA. In addition, numerous EBER-positive
Figure 1. Histopathology of joint and adjacent bone marrow tissues in hNOG mice infected with EBV. A. HE staining and EBER ISH. HE
staining of a knee joint in the EBV-infected mouse N70-13 (Table S1), showing synovial proliferation (a): a knee joint in the control mouse N69-1 not
infected with EBV (b): a knee joint in the EBV-infected mouse N87-6 (Table S1), showing a pannus-like lesion containing multinuclear giant cells
(yellow arrows) (c): and bone marrow near the knee joint of N70-13, showing edema (d). EBER ISH in the synovium of a knee joint in the EBV-infected
mouse N79-1 (Table S1), showing few EBV-infected cells (e), and in the bone marrow adjacent to the affected knee joint of the same mouse,
demonstrating a number of EBV-infected cells (f). g and h represent further magnification of a portion of e and f, respectively. The yellow arrow
indicates an EBER
+ cell. Original magnification, 6200 (a, c, d, e, f), 6100 (b). B. Immunostaining. Joint (a–e) and adjacent bone marrow tissues (f–h)
from the N70-13 mouse were examined for the expression of CD3 (a), CD4 (b, g, h), CD8 (c), CD20 (d), and CD68 (e, f). Original magnification; x200
(a–b), x400 (c–f), x100 (g), x400 (h).
doi:10.1371/journal.pone.0026630.g001
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affected joint. Thus, these results provide the first evidence that
EBV can induce erosive arthritis resembling RA in experimental
animals. We examined whether anti-cyclic citrullinated peptide
(CCP) antibodies and rheumatoid factor (RF), two major markers
of RA, were present in the blood of hNOG, but neither was
detected.
Few EBER-positive cells were detected in the synovium of
affected mouse joints and therefore it is unlikely that EBV-infected
cells elicited strong virus-specific immune responses in the
synovium and these immune responses triggered aberrant effects
damaging the surrounding tissue. However, as numerous CD4
+ T
cells, as well as EBER
+ cells, were found in the edematous bone
marrow adjacent to the affected joint, it is conceivable that
migration of inflammatory cells from bone marrow to synovium
via ostioles, as Ochi an others suggested, had a role in the initiation
of erosive arthritis [20]. It is also possible that inflammatory
cytokines produced in bone marrow diffused through the nutrient
canal or the nutrient foramen to the synovium and induce the
proliferation of synoviocytes and the activation of osteoclasts in the
adjacent joint. Significant levels (150–200 pg/ml) of IFN-c were
detected in the plasma of EBV-infected humanized mice.
Antigenic cross reaction between EBV proteins and host mouse
tissues might have been also involved in the pathogenesis of erosive
arthritis in the mice. It should be noted, however, that after
rigorous examination we have not detected anti-EBV antibodies in
EBV-infected hNOG mice, except for anti-p18
BFRF3 (the18-kDa
protein encoded by the third rightward open reading frame in the
BamHI F fragment) IgM antibody shown in four out of thirty
examined mice[15]. We did not detect antibodies to either EBNA1
that cross-reacts with a 62 kDa protein found in the synovium
affected by RA [5] or gp110 that cross-reacts with HLA-DR
[6,21]. Antigenic mimicry involving humoral immune responses
may thus be unlikely to have a major role in the pathogenesis of
erosive arthritis in hNOG mice. In contrast, we observed
abundant T-cell response to EBV infection in hNOG mice[15,16]
and it is conceivable that these strong T-cell response has some
role in the generation of erosive arthritis.
The present mouse model of erosive arthritis may be an
excellent system to investigate the pathogenesis of RA. In this
model, it is feasible to remove particular cellular or molecular
factors implicated in the pathogenesis of RA by administration of
specific antibodies or specific functional antagonists[16]. Analysis
on the effects of these antibodies or antagonists will clarify the
role of individual cellular and molecular components of the
immune system and hence give new insights to the pathogenesis
of RA. In a similar approach, this model can also be used to
search for molecular and/or cellular targets of novel therapeutics
for RA.
Supporting Information
Table S1 hNOG mice examined for the development of
arthritis.
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